+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Oncovax"

Dendritic Cell Cancer Vaccine Market Report 2025 - Product Thumbnail Image

Dendritic Cell Cancer Vaccine Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

OncoVAX is a type of cancer vaccine that is designed to stimulate the body's immune system to recognize and attack cancer cells. It is a form of immunotherapy, which is a type of treatment that uses the body's own immune system to fight cancer. OncoVAX is designed to target specific cancer cells, while leaving healthy cells unharmed. It is typically used in combination with other treatments, such as chemotherapy and radiation therapy. OncoVAX is still in the early stages of development, and is not yet widely available. Clinical trials are ongoing to evaluate its safety and efficacy. It is expected that OncoVAX will eventually become a viable treatment option for many types of cancer. Some companies in the OncoVAX market include Immunovaccine, Inc., OncoVax, Inc., and Oncolytics Biotech, Inc. Show Less Read more